Cogentix Medical Inc  

(Public, NASDAQ:CGNT)   Watch this stock  
Find more results for NASDAQ:VSCI
+0.04 (2.35%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.67 - 1.78
52 week 0.71 - 1.99
Open 1.70
Vol / Avg. 68,055.00/136,175.00
Mkt cap 46.19M
P/E     -
Div/yield     -
EPS -0.26
Shares 26.54M
Beta 0.82
Inst. own 32%
Nov 3, 2016
Cogentix Medical Inc Extraordinary Shareholders Meeting - 9:30AM EDT - Add to calendar
Sep 27, 2016
Cogentix Medical Inc at Ladenburg Thalmann Healthcare Conference
Aug 2, 2016
Q2 2016 Cogentix Medical Inc Earnings Call
Aug 2, 2016
Q2 2016 Cogentix Medical Inc Earnings Release
Jul 29, 2016
Cogentix Medical Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -20.49% -
Operating margin -17.32% -
EBITD margin - -
Return on average assets -22.38% -
Return on average equity -72.29% -
Employees 178 -
CDP Score - -


5420 Feltl Rd
MINNETONKA, MN 55343-7982
United States - Map
+1-952-4266140 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cogentix Medical, Inc., formerly Vision-Sciences, Inc., is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU). The Company offers Urgent PC Neuromodulation System, a nerve stimulation device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). It also offers Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. It markets additional bulking agents: PTQ for the treatment of fecal incontinence and the VOX for vocal cord augmentation.

Officers and directors

Darin Hammers President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Brett A. Reynolds Chief Financial Officer, Senior Vice President, Principal Financial Officer, Principal Accounting Officer, Secretary
Age: 47
Bio & Compensation  - Reuters
Kenneth H. Paulus Director
Age: 56
Bio & Compensation  - Reuters
Cheryl Pegus M.D. Director
Age: 51
Bio & Compensation  - Reuters
Lewis C. Pell Director
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kevin H. Roche Director
Age: 64
Bio & Compensation  - Reuters
Howard I. Zauberman Director
Age: 62
Bio & Compensation  - Reuters